LRPAP1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the past years, CD19 (211, 212), CD26 (213), CD38 (214), and IL-1-Receptor-associated Protein (IL-1-RAP) (215) have been investigated as potential target antigens for a CAR-T-cell therapy approach in CML.